The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer

Karoutsos Petros; Karoutsos Dimitrios; Karoutsou Eftychia

doi:10.4172/2157-2518.1000281

Awards Nomination 20+ Million Readerbase

PMC/PubMed Indexed Articles

Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells

Comparison of Pre- and Post-translational Expressions of COXIV-1 and MT-ATPase 6 Genes in Colorectal Adenoma-Carcinoma Tissues

Google Scholar citation report

Citations : 1731

Journal of Carcinogenesis & Mutagenesis received 1731 citations as per Google Scholar report

Journal of Carcinogenesis & Mutagenesis peer review process verified at publons

25+ Million Website Visitors

Indexed In

Open J Gate
Genamics JournalSeek
JournalTOCs
Ulrich's Periodicals Directory
RefSeek
Hamdard University
EBSCO A-Z
OCLC- WorldCat
Publons
Geneva Foundation for Medical Education and Research
Euro Pub
Google Scholar

Useful Links

Share This Page

Journal Flyer

Tweets by carcenogenesis

Open Access Journals

Abstract

The Mechanism of Checkpoint Inhibitors in Gynecologic Cancer

Karoutsos Petros, Karoutsos Dimitrios and Karoutsou Eftychia

Currently, immunomodulators are used in different cancer entities, including gynecologic malignancies. Toxicity is variable but of narrow extent. Among immunomodulators, checkpoint inhibitors are used to enhance the immune system and significantly improve therapeutic results of advanced disease, mounting tumor progression.